ALDX logo

ALDEYRA THERAPEUTICS INC

ALDXNASDAQ
🏆 #4214 by market capEarnings Nov 4US Equity
$1.32▲ $0.17 (+12.82%)
Market closed · at close
🔔
Track ALDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 12.8%
7d▼ 1.5%
14d▼ 5.0%
30d▼ 10.8%
ytd▼ 74.5%
1y▼ 74.7%
🏦Market Cap
$80M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$1.31 – $1.34
52-Week Range
$1.07 – $5.93
Volume
$4.28B
Avg Volume
$3.58B
Shares Outstanding
60.3M
Next Earnings
Dec 14, 2026

Fundamentals Snapshot

Annual Revenue
$19M
Last Q Revenue
$5M
P/E Ratio
-3.4
P/S Ratio
0.0x
EPS (TTM)
$-0.38
Dividend Yield
0.00%
Dilution (1yr)
+1.1%

Why Investors Own ALDX

  • ✓High-growth profile — revenue up +50.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 32% gross margin and 23% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ALDX logo

ALDEYRA THERAPEUTICS INC

ALDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$35M▼ −41.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$33M▼ −22.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
60.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55M▲ +$15M YoY
StockOtter · stockotter.space

About ALDEYRA THERAPEUTICS INC

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy5
Buy5
Hold2
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

🚀
Bloomberg·2h ago

ALDEYRA THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ALDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

ALDEYRA THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.